Pharma Blog Watch

Sanofi-Aventis' Secret ImClone Bid (PharmaGossip)
In this post, an insider blogger discusses a New York Times report that sanofi-aventis was the company that bid to acquire ImClone Systems. "Shares of ImClone soared last week after the company announced that Carl C. Icahn, who holds a stake of nearly 14 percent in the company, had scuttled a potential takeover offer of $36 a share from a 'major international pharmaceutical company' last month," the blogger notes.

"The disclosure of a would-be suitor, which ImClone did not identify, became the latest point of contention in an escalating battle between Mr. Icahn and the company."